Published data on the association of vascular endothelial growth factor (VEGF) -1154G>A polymorphism with cancer risk is inconclusive.
To derive a more precise estimation of association between VEGF -1154G>A polymorphism and the risk of cancer, we performed a meta-analysis of 7,071 cancer cases and 7,693 controls from 16 published case-control studies. Our meta-analysis didn't reveal an association between VEGF -1154G>A polymorphism and overall cancer risk (GG vs. AA: OR: 1.08, 95% CI: 0.96-1.20; GA vs. AA: OR: 1.04, 95% CI: 0.93-1.17; recessive model: GG+GA vs. AA: OR: 1.06, 95% CI: 0.95-1.18; dominant model: GG vs. GA+AA, OR: 1.11, 95% CI: 1.00-1.24). Nevertheless, for non-Caucasians, GG homozygote may have higher cancer risk compared with either A carriers (OR: 1.58, 95% CI: 1.12-2.23) or AA homozygote (OR: 1.43, 95% CI: 1.17-1.76). No significant heterogeneity was detected except in the dominant model and "prostate cancer" subgroup analysis. More studies with larger samples are warranted to confirm these findings.
Written by:
Hong TT, Zhang RX, Wu XH, Hua D. Are you the author?
Department of Medical Oncology, The Fourth Affiliated Hospital of Suzhou University, Huihe Road 200, Wuxi, 214062, China. .
Reference: Mol Biol Rep. 2011 Dec 14. [Epub ahead of print]
PubMed Abstract
PMID: 22167330
UroToday.com Investigational Urology Section
